

Two- and 13-week Inhalation Toxicities of Indium-tin Oxide and Indium Oxide in Rats

Kasuke NAGANO¹, Kaoru GOTOH¹, Tatsuya KASAI¹, Shigetoshi AISO¹, Tomoshi NISHIZAWA¹, Makoto OHNISHI¹, Naoki IKAWA¹, Yoko EITAKI², Kenichi YAMADA², Heihachiro ARITO¹ and Shoji FUKUSHIMA¹

¹Japan Bioassay Research Center, Japan Industrial Safety and Health Association and ²Occupational Health Research and Development Center, Japan Industrial Safety and Health Association, Japan

Abstract: Two- and 13-week Inhalation Toxicities of Indium-tin Oxide and Indium Oxide in Rats: Kasuke NAGANO, et al. Japan Bioassay Research Center, Japan Industrial Safety and Health Association—

Objectives: Two- and 13-week inhalation toxicities of indium-tin oxide (ITO) and indium oxide (IO) were characterized for risk assessments of workers exposed to ITO. **Methods:** F344 rats of both sexes were exposed by inhalation to ITO or IO aerosol for 6 h/day, 5 day/wk for 2 wk at 0, 0.1, 1, 10 or 100 mg/m³ or 13 wk at 0, 0.1 or 1 mg/m³. An aerosol generator and inhalation exposure system was constructed. **Results:** Blood and lung contents of indium were elevated in a dose-related manner in the ITO- and IO-exposed rats. ITO and IO particles were deposited in the lung, mediastinal lymph node and nasal-associated lymphoid tissue. Exposures to ITO and IO induced alveolar proteinosis, infiltrations of alveolar macrophages and inflammatory cells and alveolar epithelial hyperplasia in addition to increased lung weight. ITO affected the lung more severely than IO did. Fibrosis of alveolar wall developed and some of these lesions worsened at the end of the 26-week post-exposure period. **Conclusions:** Persistent pulmonary lesions including alveolar proteinosis and macrophage infiltration occurred after 2- and 13-week inhalation exposures of rats to ITO and IO. Fibrosis of alveolar wall developed later. These lesions occurred after ITO exposure at the same concentration as the current occupational exposure limit in the USA and at blood indium levels below the biological exposure index in Japan for indium. (J Occup Health 2011; 53: 51–63)

Key words: Indium-tin oxide, Indium oxide, Inhalation, Pulmonary toxicity, Rat

Indium-tin oxide (ITO), a sintered material containing 90% indium oxide (IO) and 10% tin oxide, has been extensively used in liquid-crystal displays and other display devices. The average annual growth of the use of indium in the form of ITO has increased by an average 18 percent per year¹. The technology used to create ITO targets and ITO thin film applications gives rise to potential exposure to ITO particles, and poses a serious threat to the health of workers engaged in the manufacturing, processing and handling of ITO. Two fatal case studies have been reported. An operator of wet surface grinding in an ITO plant was diagnosed as interstitial pneumonia and died of bilateral pneumothorax², and a furnace operator in an ITO plant died of respiratory failure due to pulmonary alveolar proteinosis³. Recent epidemiological studies on the health of workers in ITO plants have demonstrated a potential cause of occupational lung disease as inhaled indium and an increased risk for interstitial lung damage by ITO inhalation^{4–7}. Experimental toxicology studies have revealed that an administration of ITO causes persistent inflammation in the lung of rats⁸, a strong cytotoxic response of macrophages *in vitro* by generation of reactive oxygen species (ROS)⁸, and a pulmonary inflammatory response with diffuse bronchiolar and alveolar hyperplasia and interstitial fibrotic proliferation in hamsters^{9,10}. An intratracheal administration of indium trichloride to rats was reported to initiate an inflammatory response with rapid development of fibrosis¹¹. The National Toxicology Program's (NTP's) 14-week study¹² showed that inhalation exposure of rats to indium phosphide aerosol induces inflammation and alveolar proteinosis in the lung.

Inhalation is a principal route of exposure for workers in the facilities where ITO is manufactured, processed and

Received Sep 17, 2010; Accepted Nov 15, 2010

Published online in J-STAGE Jan 11, 2011

Correspondence to: T. Nishizawa, Japan Bioassay Research Center, Japan Industrial Safety and Health Association, 2445 Hirasawa, Hadano, Kanagawa 257-0015, Japan
(e-mail: t-nishizawa@jisha.or.jp)

handled. In order to protect workers from inhalation exposure to indium and its compounds, an occupational exposure limit (OEL) of 0.1 mg/m^3 has been recommended as the Threshold Limit Value-Time Weighted Average (TLV-TWA) by the American Conference of Governmental Industrial Hygienists (ACGIH)¹³, and as the Recommended Exposure Limit (REL) by the National Institute for Occupational Safety and Health (NIOSH)¹⁴. The Japan Society for Occupational Health (JSOH)¹⁵ has recommended a serum indium level of $3 \text{ } \mu\text{g/l}$ as a biological exposure index (BEI). It is of prime importance to provide basic animal toxicity data showing the dose-response relationships between concentrations of inhalation exposure of rats and mice to ITO and its major component, IO, target tissue doses of indium and resulting pulmonary toxic responses to these two aerosols.

In order to assess the health risks of workers exposed by inhalation to ITO and IO aerosols in the work environment, the present studies were intended to characterize subacute and subchronic inhalation toxicities of ITO and IO in rats and to provide dose-response relationships between aerosol concentrations of inhalation exposure to ITO and IO aerosols, lung and blood contents of indium and resulting pulmonary lesions. For this purpose, we constructed an aerosol generation and exposure system for providing inhalation exposure of unrestrained rats and mice to aerosols of ITO and IO at strictly controlled exposure concentrations ranging from 0.1 to 100 mg/m^3 . And, we conducted inhalation exposures of male and female rats to dry aerosols of ITO and IO at these concentrations for 2 and 13 wk. A further purpose of the present studies was to predict an appropriate range of exposure concentrations of ITO aerosol for a 2-year rodent carcinogenicity study, based on the results.

Materials and Methods

The present studies were conducted in accordance with the Organization for Economic Cooperation and Development's (OECD's) Good Laboratory Practice¹⁶, and with reference to the OECD's Guidelines for Testing of Chemicals 412 "Repeated Dose Inhalation Toxicity, 28-day or 14-day Study"¹⁷ and 413 "Subchronic Inhalation Toxicity, 90-day Study"¹⁸. The animals were cared for in accordance with the Guide for the Care and Use of Laboratory Animals¹⁹ and the present studies were approved by the ethics committee of the Japan Bioassay Research Center.

Test materials

Powders of ITO and IO were kindly supplied by JX Nippon Mining & Metals, Corp. (former Nippon Mining & Metals Co., Ltd.) (Tokyo, Japan). ITO powder was prepared by grinding the sintered ITO plate, and was colored with black. The mean diameter of the powder was $3.5 \text{ } \mu\text{m}$ with a 90% cumulative diameter of $8.9 \text{ } \mu\text{m}$. The

sintered ITO powder was composed of 90.06% IO and 9.74% SnO_2 . Its purity was 99.8% with trace amounts of aluminium, chromium, copper, iron, nickel, lead, silica, zirconium and zinc as impurities. IO powder was colored with yellow, and had a mean diameter of $1.4 \text{ } \mu\text{m}$ with a 90% cumulative diameter of $2.9 \text{ } \mu\text{m}$. The purity of the IO powder was 99.9% with trace amounts of tin, silica and lead as impurities.

Animals

F344/DuCrIj rats of both sexes were obtained at the age of 4 wk from Charles River Japan, Inc (Kanagawa, Japan). The animals were quarantined and acclimated for 2 wk before the start of experiment. The animals were housed individually in stainless-steel wire hanging cages ($170 \text{ W} \times 294 \text{ D} \times 176 \text{ H mm}$), which were placed in a stainless steel inhalation exposure chamber of 1,060 liters in volume. The environment in the exposure chamber was maintained constant at a temperature of $20\text{--}24^\circ\text{C}$ and a relative humidity of 30–70% with 12 air changes/h. The exposure chambers were installed in a barrier system animal room. Fluorescent lighting was controlled automatically to give a 12-hour light/dark cycle. All rats were given sterilized commercial pellet diet (CRF-1, Oriental Yeast Co., Ltd., Tokyo, Japan) and sterilized water *ad libitum*.

Experimental design

In the 2-week study, groups of 5 rats of each sex were exposed to ITO or IO aerosol at a target concentration of 0.1 , 1 , 10 or 100 mg/m^3 as ITO or IO for 6 h/day, 5 day/wk for 2 wk. In the 13-week study, groups of 10 rats of each sex were exposed to ITO or IO aerosol at a target concentration of 0.1 or 1 mg/m^3 for 6 h/day, 5 day/wk for 13 wk. Groups of 5 or 10 rats of each sex were exposed to clean air for 2 or 13 wk under the same conditions, and served as respective controls. In order to evaluate recovery from the subchronic effects after cessation of the 13-week exposure to ITO, a post-exposure group of 10 rats of each sex was set up, which was exposed to ITO at 0.1 mg/m^3 for 13 wk and then to clean air for 26 wk. Ten rats of each sex serving as respective controls were handled in the same manner as the post-exposure group, but were exposed to clean air for 39 wk.

Aerosol generation and exposure to ITO and IO

Two different systems for generation of ITO or IO aerosol and inhalation exposure were used in the present studies. A target aerosol concentration of 100 mg/m^3 was generated using a system illustrated in the upper part (A) of Fig. 1. It consisted of a dust feeder equipped with an ejector, an exposure chamber and a digital dust indicator (Type AP-632T, Sibata Scientific Technology, Ltd., Tokyo, Japan). Airflow containing the aerosol was generated by drawing the powder with compressed clean air at the first




Fig. 1. A schematic diagram of the aerosol generation, regulation and inhalation exposure systems. (A) A system used for aerosol generation of a high aerosol concentration of 100 mg/m^3 . (B) Another system used for generation of lower concentrations of 10, 1 and 0.1 mg/m^3 . Thick, thin and dotted arrows indicate aerosol flow, sampling of chamber air for monitoring aerosol concentration and feedback control, respectively. Components of the systems: a) reservoir chamber, b) inhalation exposure chamber, c) digital dust indicator, d) dust feeder with an ejector, e) ejector, f) flowmeter, g) flow control valve, h) solenoid valve, i) HEPA filter.

ejector and introduced into the top of the exposure chamber where the filtered air had been kept flowing downward at 12 air changes/h. The mass-equivalent concentration of ITO or IO in the exposure chamber was monitored with the digital dust indicator. In order to keep the aerosol concentration constant in the exposure chamber during the 6-hour exposure period, a feedback control system between the digital dust indicator and the dust feeder was set up. When the chamber concentration went above an upper limit of a normal concentration range, the dust feeder stopped supplying the powder. Conversely, when the chamber concentration fell below the lower limit, the dust feeder started to supply the powder. Chamber concentrations of 10, 1 and 0.1 mg/m^3 were generated

using another system illustrated in the lower part (B) of Fig. 1. It consisted of the first-stage system (a, c and d in Fig. 1B) for aerosol generation of a high concentration at 100 mg/m^3 and a further dilution system. Aerosol generation of the high concentration and its regulation were performed in the same manner described above, and airflow containing the aerosol was delivered to a reservoir chamber for stabilization of the aerosol concentration. The airflow containing the aerosol was delivered to the second ejector and then introduced into the top of the exposure chambers where the filtered air had been kept flowing downward at 12 air changes/h. The aerosol concentration in the exposure chamber was monitored with the second digital dust indicator and regulated at a target concentration of 10, 1 or 0.1 mg/m^3 . The aerosol concentration was stabilized by setting up the second feedback system between the digital dust indicator and a solenoid valve which regulated the flow rate of compressed clean air entering the second ejectors. The exposure chambers were kept at a negative pressure (-100 Pa), in order to prevent leakage of ITO and IO aerosols into the outside air. Exhaust air from the exposure chamber was passed through a HEPA filter to remove ITO and IO particles before release into the atmosphere. The concentrations of indium in the exhaust air were below the detection limit of 0.0001 mg/m^3 after the treatment with the HEPA filter.

Chamber concentrations and size distribution of ITO and IO aerosols

In order to determine concentrations of ITO or IO aerosol in the exposure chamber, ITO or IO particles were collected on a filter (Teflon binder T60A20, Sibata Scientific Technology, Ltd, Tokyo, Japan) on Days 1 and 8 in the 2-week study and every week in the 13-week study. The particles on the filter were dissolved in a mixture solution of distilled water, hydrochloric acid and nitric acid (2:2:1 by volume ratio) at 160°C . The resulting solution was diluted with nitric acid, and then subjected to atomic absorption spectrometry analysis (Polarized Zeeman Atomic Absorption Spectrophotometer, Z-5010, Hitachi High-Technol. Co., Tokyo, Japan). Exposure chamber concentrations of ITO and IO aerosols were derived from the measured levels of elemental indium as shown in Table 1.

Measurement of the size distribution of ITO or IO aerosol in the exposure chamber was carried out once in the 2-week study and in the 4th and 8th wk in the 13-week study. ITO or IO aerosol was collected with an 8-stage Andersen sampler (Type AN200, Sibata Scientific Technology, Ltd). Using the mass of the particles on the filter (Teflon binder T60A20, Sibata Scientific Technology, Ltd) collected at each stage of the Andersen sampler, mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were determined.

Table 1. Mass concentrations and mass median aerodynamic diameters (MMADs) and geometric standard deviations (GSDs) of ITO and IO aerosols in the exposure chamber

Dose	ITO				IO			
	Mass concentration (mg/m ³) (Mean ± SD)	Aerodynamic diameter			Mass concentration (mg/m ³) (Mean ± SD)	Aerodynamic diameter		
		Median (μm)	GSD		Median (μm)	GSD		
2-week study	In a)				In a)			
0.1 mg/m ³	0.09 ± 0.00	0.07 ± 0.00	2.5	1.8	0.10 ± 0.01	0.08 ± 0.01	1.9	1.7
1 mg/m ³	0.94 ± 0.02	0.70 ± 0.01	2.7	1.8	1.07 ± 0.06	0.89 ± 0.05	2.1	1.8
10 mg/m ³	9.33 ± 0.33	6.94 ± 0.25	3.0	1.8	10.76 ± 0.46	8.90 ± 0.38	2.1	1.8
100 mg/m ³	95.90 ± 2.99	71.35 ± 2.22	3.7	1.9	105.25 ± 7.01	87.04 ± 5.80	2.2	1.7
13-week study								
0.1 mg/m ³	0.10 ± 0.01	0.07 ± 0.01	2.4	1.8	0.10 ± 0.01	0.08 ± 0.01	2.1	1.7
1 mg/m ³	1.01 ± 0.08	0.75 ± 0.06	2.5	1.9	1.01 ± 0.09	0.84 ± 0.07	2.3	1.7

a): Mass concentration as indium.

Determination of indium concentrations in the lung and blood

Lung indium was quantified in the 2-week study, and both the lung and whole-blood were analyzed for indium in the 13-week study. Cranial, caudal and accessory lobes of the right lung were used for the analysis. A sample of the lung or 1.0 ml of blood was added with ultra-pure nitric acid and digested with a microwave digestion apparatus (Microwave Digestion System, Model 7295, O-I-Analytical, CA, USA). The digested sample was added with ultra-pure water and injected into an inductively coupled plasma mass spectrometer (ICP-MS) (Type 7500i, Agilent Technologies, Ltd., CA, USA). Cesium was used as an internal standard for the indium measurement. The quantitative detection limit of indium was 0.006 μg/g for lung tissue and 0.5 μg/l for whole-blood. Lung indium was expressed as both a concentration of indium per gram of lung tissue and the content of indium in the whole-lung.

Clinical observations and pathological examinations

The animals were observed daily for their clinical signs and mortality. Body weight and food consumption were measured weekly throughout the study periods. Animals surviving to the end of the 2- or 13-week exposure period and to the end of the 26-week post-exposure period received complete necropsy. Blood was collected for blood indium, hematology and blood biochemistry from the abdominal aorta under etherization. The organs and tissues designated in the OECD test guidelines^{17, 18)} were examined macroscopically and microscopically. The tissues were fixed in 10% neutral buffered formalin, and embedded in paraffin. Tissue sections of 5 μm in thickness were prepared, and stained with hematoxylin and eosin (H & E). The sections of lung tissue were also stained with a periodic acid Schiff (PAS) reagent. Lesions of the lung and lymph nodes were evaluated for their severities, scoring on a scale of "slight" to "severe" with reference to the criteria of non-neoplastic lesions by Shackelford *et al.*²⁰⁾

Statistical analysis

Body weight, organ weight, and hematological and blood biochemical parameters were analyzed by Dunnett's test as described previously²¹⁾. Histopathological findings in the 13-week study were analyzed by chi-square test. A two-tailed test was used for all statistics. In all cases, a *p* value of 0.05 was used as the level of significance.

Results

Exposure chamber concentrations and size distributions of ITO and IO aerosol

Table 1 shows the mass concentrations derived from the measured levels of elemental indium (mean ± SD), MMADs and GSDs of ITO and IO aerosols in the exposure chamber. The exposure concentrations of ITO and IO aerosols were found to be regulated precisely within less than 10% in the variation coefficient and accurately within less than 10% deviation from the target concentrations. MMADs of the ITO aerosol tended to slightly increase with an increase in the chamber concentrations, while the GSDs were constant at all exposure concentrations. On the other hand, MMADs and GSDs of IO aerosol were constant over a wide range of exposure concentrations, and MMADs of IO aerosol were slightly smaller than those of ITO aerosol.

Indium concentrations in the lung and blood

Table 2 shows lung and blood contents of indium in the male and female rats exposed to ITO and IO for 2 and 13 wk. Lung contents of indium expressed as μg/g lung tissue and μg/whole-lung were increased with an increase in the concentration of exposure to ITO or IO, but the exposure concentration-related increase was smaller in the unit of μg/g lung tissue than in that of μg/whole-lung, because the lung weights of the exposed rats were significantly heavier, up to 2-fold heavier than those of the control groups, depending on the exposure concentration (Fig. 2). In the 2-week study, the whole-lung contents of indium in the

Table 2. Lung and blood contents of indium in the male and female rats exposed to ITO or IO at 4 different concentrations for 2 wk, in those exposed to ITO or IO at 0.1 or 1 mg/m³ for 13 wk, and in those exposed to ITO at 0.1 mg/m³ for 13 wk followed by exposure to clean air for 26 wk

Group name (mg/m ³)	2-week study				13-week study		
	0.1	1	10	100	0.1	0.1 (P)	1
No. of animals examined	5	5	5	5	10	10	10
<ITO>							
Male							
Lung ($\mu\text{g/g}$ as In)	3.3 \pm 0.3	32.4 \pm 2.7	127.6 \pm 17.7	470.3 \pm 58.1	24.0 \pm 2.7	8.8 \pm 1.1	74.4 \pm 10.5
Lung ($\mu\text{g/whole-lung}$ as In)	2.4 \pm 0.1	31.1 \pm 1.8	165.1 \pm 9.8	688.3 \pm 43.1	38.7 \pm 4.6	15.0 \pm 2.0	173.9 \pm 28.6
Blood ($\mu\text{g/l}$ as In)	–	–	–	–	0.77 \pm 0.09	1.04 \pm 0.10	3.39 \pm 0.33
Female							
Lung ($\mu\text{g/g}$ as In)	2.9 \pm 0.4	34.8 \pm 8.8	148.0 \pm 41.2	533.9 \pm 69.1	22.9 \pm 2.2	8.6 \pm 1.0	79.9 \pm 7.1
Lung ($\mu\text{g/whole-lung}$ as In)	1.8 \pm 0.2	28.1 \pm 7.2	157.4 \pm 41.9	658.7 \pm 70.9	26.3 \pm 2.7	10.3 \pm 1.1	134.6 \pm 8.0
Blood ($\mu\text{g/l}$ as In)	–	–	–	–	1.13 \pm 0.32	1.46 \pm 0.26	4.06 \pm 0.56
<IO>							
Male							
Lung ($\mu\text{g/g}$ as In)	5.3 \pm 0.5	61.3 \pm 11.1	261.7 \pm 7.2	1124.7 \pm 49.3	18.0 \pm 2.3	–	144.2 \pm 15.7
Lung ($\mu\text{g/whole-lung}$ as In)	3.7 \pm 0.3	45.1 \pm 5.7	324.5 \pm 20.0	1689.2 \pm 64.2	17.2 \pm 2.8	–	235.5 \pm 34.0
Blood ($\mu\text{g/l}$ as In)	–	–	–	–	ND	–	0.76 \pm 0.08
Female							
Lung ($\mu\text{g/g}$ as In)	5.0 \pm 0.3	52.8 \pm 3.2	267.0 \pm 25.5	1190.8 \pm 51.0	13.4 \pm 1.5	–	130.6 \pm 15.7
Lung ($\mu\text{g/whole-lung}$ as In)	3.1 \pm 0.2	33.8 \pm 3.2	263.8 \pm 26.7	1464.1 \pm 88.2	9.8 \pm 1.0	–	157.3 \pm 17.4
Blood ($\mu\text{g/l}$ as In)	–	–	–	–	ND	–	0.96 \pm 0.26

(P): Data at the end of the 26-week post-exposure period. Values indicate mean \pm SD. ND: Contents were below the quantitative detection limit (0.5 $\mu\text{g/l}$). –: Not examined.

ITO- and IO-exposed groups of both sexes were not increased in a manner proportional to the exposure concentration. The whole-lung contents of indium were lower in the ITO-exposed groups than in the IO-exposed groups of both sexes at all exposure concentrations. In the 13-week study, the exposure concentration-related increase in the whole-lung content of indium was also disproportionately lowered to greater extent in the ITO-exposed rats than in the IO-exposed rats. Unlike the result from the 2-week study, the whole-lung contents of indium in the 0.1 mg/m³ ITO-exposed rats of both sexes were higher than those of the 0.1 mg/m³ IO-exposed rats of both sexes. The whole-lung contents of indium in the ITO-exposed rats of both sexes measured at the end of the 26-week post-exposure period were lowered to 40% as compared with those measured at the end of the 13-week exposure.

Table 2 also shows the blood contents of indium in the male and female rats at the end of 13-week exposures to ITO and IO at 0.1 and 1 mg/m³ as well as those exposed to ITO at 0.1 mg/m³ for 13 wk and then to clean air for 26 wk. The blood contents of indium in the 0.1 mg/m³ IO-exposed

rats of both sexes were below the quantitative detection limit of 0.5 $\mu\text{g/l}$. The blood contents of indium in the 1 mg/m³ ITO-exposed groups of both sexes were 4-fold higher than those in 1 mg/m³ IO-exposed group of both sexes. The blood contents of indium in the 0.1 mg/m³ ITO-exposed rats of both sexes measured at the end of the 26-week post-exposure period were 1.3-fold higher than those measured at the end of the 13-week exposure period.

Mortality and clinical signs in the 2- and 13-week studies

Neither death nor abnormal clinical sign, such as irregular sounds of respiration, was observed in any group exposed to ITO or IO for 2 or 13 wk. There was no growth retardation in any group exposed to ITO or IO for 2 or 13 wk as compared with the growth rate in the respective control.

Hematological and blood biochemical changes in the 2- and 13-week studies

In the 2-week study, white blood cell counts in the 100




Fig. 2. Relative lung weights: A) in the rats of both sexes exposed to ITO or IO aerosol at 0, 0.1, 1, 10 or 100 mg/m³ for 2 wk, B) in the rats of both sexes exposed to ITO or IO aerosol at 0, 0.1 or 1 mg/m³ for 13 wk. (P) represents the rats of both sexes exposed to ITO aerosol at 0 or 0.1 mg/m³ for 13 wk and subsequently to clean air for 26 wk.

mg/m³ ITO-exposed male rats and red blood cell counts, hemoglobin and hematocrit values in the 100 mg/m³ IO-exposed male rats were significantly increased compared with the respective control groups. In the 13-week study, potassium was significantly decreased in both 0.1 and 1 mg/m³ ITO- and IO-exposed rats. In addition, significant decreases in sodium and chlorine in the 0.1 and 1 mg/m³ IO-exposed male rats and significantly decreased triglyceride in the 0.1 and 1 mg/m³ IO-exposed female rats were also observed (data not shown).

Pathological findings in the 2-week study

Relative lung weights were significantly increased in the male and female rats exposed to ITO at 1 mg/m³ and above compared with the respective control groups,

whereas significantly increased lung weights were noted in the rats of both sexes exposed to IO only at 10 and 100 mg/m³ compared with the respective control groups (Fig. 2-A). Increases in absolute lung weights were indicated as well (data not shown).

Microscopic examination revealed that ITO and IO particles were deposited in the lungs of all the exposed rats except those exposed to the 0.1 mg/m³ (Table 3). The particles were pale brown and transparent, looked like amber, and were located primarily within the alveolar macrophages (Fig. 3-1) and partly as a free form in the alveolar space. Both ITO and IO particles were deposited separately as single particles. ITO and IO particles were also observed to lesser extent in the bronchus-associated lymphoid tissue (BALT) of the lung, in the mediastinal lymph nodes (MLN) and in the nasal-associated lymphoid tissue (NALT) of the nasopharyngeal duct. The particles were located within macrophages, and notably, degenerative alveolar macrophages engulfing the particles were often observed (Fig. 3-1). The most remarkable lesion found in the present 2-week study was alveolar proteinosis characterized by filling of the alveolar space with a granular, pale eosinophilic material in the ITO- and IO-exposed rats. The diagnosis of alveolar proteinosis was based on the positive staining of eosinophilic material in the alveolar space with a PAS reagent. Alveolar proteinosis was observed in the 1, 10 and 100 mg/m³ ITO-exposed rats and in the 10 and 100 mg/m³ IO-exposed rats, and its severity score was increased dose-dependently in both the ITO- and IO-exposed groups. Incidences of alveolar macrophage infiltration in the ITO and IO-exposed rats were increased at the same exposure concentrations as the occurrence of alveolar proteinosis. Infiltration of inflammatory cells which were primarily composed of neutrophils and lymphocytes was observed in the alveolar space and wall of almost all the 10 and 100 mg/m³ ITO- and IO-exposed rats of both sexes. Hyperplasia of alveolar epithelium occurred in some 10 and 100 mg/m³ ITO- and IO-exposed rats, and was characterized by increased numbers of cuboidal cells, which were assumed to be type II pneumocytes, and by their location in the focal lung areas accompanied by infiltrations of alveolar macrophages and inflammatory cells. Those alveolar macrophages had foamy cytoplasm.

Pathological findings in the 13-week study

Relative lung weights were significantly increased in all the rats of both sexes exposed to ITO and IO at 0.1 and 1 mg/m³ compared with the respective control groups (Fig. 2-B). The increase in the relative lung weight was more marked in the ITO-exposed rats of both sexes than in the IO-exposed rats. Increases in absolute lung weights were observed as well (data not shown).

Microscopic examination revealed that ITO and IO particles were deposited in the lungs of all the exposed

Table 3. Histopathological findings in the lung and lymph nodes of male and female rats exposed to ITO or IO at 4 different concentrations or clean air for 2 wk

Group name (mg/m ³) No. of animals examined	ITO					IO				
	Control	0.1	1	10	100	Control	0.1	1	10	100
<Male>										
Deposition of particles										
Lung	0	0	5	5	5	0	0	5	5	5
BALT	0	0	0	1	5	0	0	0	3	5
MLN	0	0	0	2	5	0	0	0	3	5
NALT	0	0	0	1	5	0	0	0	5	5
Histopathological findings										
Lung										
Alveolar proteinosis	0	0	5	5	5	0	0	0	5	5
			<1.0>	<2.0>	<2.0>				<1.8>	<2.0>
Infiltration of alveolar macrophages	0	0	5	5	5	0	0	0	5	5
			<1.0>	<1.0>	<1.0>				<1.0>	<1.0>
Infiltration of inflammatory cells	0	0	0	5	5	0	0	0	4	5
				<1.2>	<1.0>				<1.3>	<1.2>
Hyperplasia of alveolar epithelium	0	0	0	3	4	0	0	0	3	1
				<1.0>	<1.0>				<1.0>	<1.0>
<Female>										
Deposition of particles										
Lung	0	0	5	5	5	0	0	5	5	5
BALT	0	0	0	0	4	0	0	0	3	5
MLN	0	0	0	2	3	0	0	0	3	5
NALT	0	0	0	0	3	0	0	0	3	3
Histopathological findings										
Lung										
Alveolar proteinosis	0	0	5	5	5	0	0	0	5	5
			<1.0>	<2.0>	<2.0>				<1.8>	<2.0>
Infiltration of alveolar macrophages	0	0	5	5	5	0	0	2	5	5
			<1.0>	<1.0>	<1.0>			<1.0>	<1.0>	<1.0>
Infiltration of inflammatory cells	0	0	1	5	5	0	0	0	5	5
			<1.0>	<1.2>	<1.0>				<1.0>	<1.0>
Hyperplasia of alveolar epithelium	0	0	0	3	2	0	0	0	3	0
				<1.0>	<1.0>				<1.0>	

Values indicate number of animals bearing lesions. The values in angle bracket indicate the average of severity grade index of the lesion. The average of severity grade is calculated with a following equation. $\Sigma(\text{grade} \times \text{number of animals with grade}) / \text{number of affected animals}$. Grade: 1, slight; 2, moderate; 3, marked; 4, severe. BALT: Bronchus-associated lymphoid tissue. MLN: Mediastinal lymph nodes. NALT: Nasal-associated lymphoid tissue.

rats of both sexes (Table 4). The particles were located primarily within the alveolar macrophages and partly as a free form within the alveolar space. ITO and IO particles were also observed to a lesser extent in the BALT of the 0.1 and 1 mg/m³ ITO- exposed and 1 mg/m³ IO-exposed rats, in the MLN of both 0.1 and 1 mg/m³ ITO- and IO-exposed rats, and in the NALT of the 1 mg/m³ ITO- and IO-exposed rats. Alveolar proteinosis occurred in all the ITO-exposed rats and in the 1 mg/m³ IO-exposed rats (Fig.

3-2). The severity score of alveolar proteinosis of the 0.1 mg/m³ ITO-exposed rats was equal to that of the 1 mg/m³ IO-exposed rats. Infiltration of alveolar macrophages was observed in the 0.1 and 1 mg/m³ ITO- and IO-exposed rats. Notably, swelling of cytoplasm in the alveolar macrophages was evidently recognized, indicating degeneration of the macrophages. Some alveolar macrophages contained PAS-positive, eosinophilic material in the cytoplasm. A significant increase in




Fig. 3. 1) Microphotographs showing the presence of particles (arrowheads) in the alveolar macrophages in the lung of a male rat exposed to ITO at 100 mg/m³ for 2 wk (A) and in the lung of another rat exposed to IO at 100 mg/m³ for 2 wk (B). Note that alveolar macrophages engulfing the particles (open arrows) are degenerative (filled arrows). H & E stain. Bar indicates 50 μ m. 2) Microphotographs showing alveolar proteinosis in the lung of a male rat exposed to ITO at 0.1 mg/m³ for 13 wk, stained with H & E (A) and in the lung of the same rat stained with a PAS reagent (B). Bar indicates 100 μ m. 3) A microphotograph showing a low power view of a focal lesion (arrow) located beneath the pleural wall in a male rat exposed to ITO at 0.1 mg/m³ for 13 wk and then exposed to clean air for 26 wk. H & E stain. Bar indicates 500 μ m. 4) A microphotograph showing a high power view of alveolar wall fibrosis, alveolar epithelial hyperplasia, and alveolar macrophage infiltration in a male rat exposed to ITO at 0.1 mg/m³ for 13 wk and then exposed to clean air for 26 wk. Note the alveolar wall fibrosis indicating an increase in collagen-like connective tissue (thick filled arrow), hyperplasia of alveolar epithelium (thin filled arrow), cholesterol cleft (arrowhead) and swelling of cytoplasm in alveolar macrophages (open arrow). H & E stain. Bar indicates 50 μ m.

inflammatory cell infiltration was observed in the 1 mg/m³ ITO- and IO-exposed rats, and these incidences were higher in the ITO-exposed rats than in the IO-exposed rats. Hyperplasia of alveolar epithelium occurred mainly in some rats exposed to ITO at 0.1 mg/m³ and in the 1 mg/m³ IO-exposed rats. Small granulomas composed of particle-laden macrophages were observed in the MLN of the 0.1 and 1 mg/m³ ITO-exposed rats and in the 1 mg/m³ IO-exposed rats.

Pathological findings at the end of the 26-week post-exposure period

Relative lung weights were significantly increased in

the exposed rats at the end of the 26-week post-exposure period as compared with those of respective controls (denoted as (P) in Fig. 2-B).

Microscopic examination revealed the presence of ITO particles in the lung, BALT and MLN of the exposed rats at the end of the 26-week post-exposure period (denoted as (P) in Table 4). All the lesions seen in the lung and lymph nodes/tissue of the 0.1 mg/m³ ITO-exposed group at the end of the 13-week exposure period persisted throughout the 26-week post-exposure period. A focal lesion composed of alveolar wall fibrosis, alveolar epithelial hyperplasia, infiltrations of alveolar macrophages and inflammatory cells was observed beneath the pleural

Table 4. Histopathological findings in the lung and lymph nodes of male and female rats exposed to ITO or IO at 0, 0.1 or 1 mg/m³ for 13 wk, or exposed to ITO at 0.1 mg/m³ for 13 wk followed by exposure to clean air for 26 wk

Group name (mg/m ³) No. of animals examined	ITO						IO		
	13 wk			13 wk (P)			13 wk		
	Control	0.1	1	Control	0.1	Control	0.1	1	
	10	10	10	10	10	10	10	10	
<Male>									
Deposition of particles									
Lung	0	10	10	0	10	0	10	10	
BALT	0	9	9	0	7	0	0	10	
MLN	0	7	9	0	9	0	0	10	
NALT	0	0	2	0	0	0	0	2	
Histopathological findings									
Lung									
Alveolar proteinosis	0	10 **	10 **	0	10 **	0	0	10**	
		<2.0>	<3.0>		<1.7>			<2.0>	
Infiltration of alveolar macrophages	0	10 **	10 **	0	10 **	0	6 *	10**	
		<1.1>	<2.0>		<1.3>		<1.0>	<1.0>	
Infiltration of inflammatory cells	0	2	10 **	0	4	0	0	5 *	
		<1.0>	<1.0>		<1.0>			<1.0>	
Hyperplasia of alveolar epithelium	0	2	0	0	10 **	0	0	6 *	
		<1.0>			<1.3>			<1.0>	
Granuloma of BALT	0	0	1	0	0	0	0	0	
			<1.0>						
Fibrosis of alveolar wall	0	0	0	0	10 **	0	0	0	
					<1.0>				
Thickening of pleura	0	0	0	0	0	0	0	0	
Lymph nodes									
Granuloma of MLN	0	5 *	7 **	0	5 *	0	0	5 *	
		<1.0>	<1.0>		<1.0>			<1.0>	

(P): Data at the end of the 26-week post-exposure period. Note: Values indicate number of animals bearing lesions. The values in angle bracket indicate the average of severity grade index of the lesion. The average of severity grade is calculated with a following equation. $\Sigma(\text{grade} \times \text{number of animals with grade}) / \text{number of affected animals}$. Grade: 1, slight; 2, moderate; 3, marked; 4, severe. Significant difference: *, $p \leq 0.05$; **, $p \leq 0.01$ by Chi-square test. BALT: Bronchus-associated lymphoid tissue. MLN: Mediastinal lymph nodes. NALT: Nasal-associated lymphoid tissue.

wall (Fig. 3-3 and -4). Fibrosis of alveolar wall in all the exposed rats and thickening of pleural wall in one exposed female rat were evidently recognized only at the end of the 26-week post-exposure period, and were characterized by an increase in collagen-like connective tissue in the alveolar (Fig. 3-4) and pleural wall, respectively. It was noteworthy that cholesterol cleft (Fig. 3-4) was often observed in the same alveolar region at the end of the 26-week post-exposure period. The incidences and severities of alveolar epithelial hyperplasia were increased in the 26-week post-exposure groups as compared with that at the end of the 13-week exposure period.

No exposure-related histopathological changes were observed in any other organ or tissue in the ITO- or IO-exposed rats of either sex in the 2- and 13-week studies

or at the end of the 26-week post-exposure period.

Discussion

The present system of aerosol generation and inhalation exposure was found to generate ITO and IO aerosols at the reproducible exposure concentrations regulated precisely within 10% coefficient of variation and accurately within 10% deviation from the target concentrations. Thus, this system allows to repeatedly expose individually housed, unrestrained rats of both sexes to ITO or IO particles of micron size at a wide range of concentrations from 0.1 to 100 mg/m³ in large inhalation exposure chambers (1 m³) for a time period of up to 90 days. The aerosols of ITO and IO in the exposure chamber were not aggregated and were well-dispersed to single particles of about 2–3 μm in

Table 4. continued

Group name (mg/m ³) No. of animals examined	ITO					IO		
	13 wk			13 wk (P)		13 wk		
	Control	0.1	1	Control	0.1	Control	0.1	1
<Female>								
Deposition of particles								
Lung	0	10	10	0	10	0	10	10
BALT	0	3	10	0	10	0	0	10
MLN	0	9	10	0	7	0	2	10
NALT	0	0	6	0	0	0	0	3
Histopathological findings								
Lung								
Alveolar proteinosis	0	10 **	10 **	0	10 **	0	0	10**
		<2.0>	<3.0>		<1.9>			<2.0>
Infiltration of alveolar macrophages	0	10 **	10 **	0	10 **	0	2	10**
		<1.0>	<2.0>		<1.5>		<1.0>	<1.0>
Infiltration of inflammatory cells	0	2	10 **	0	10 **	0	0	7 **
		<1.0>	<1.0>		<1.0>			<1.0>
Hyperplasia of alveolar epithelium	0	5 *	1	0	10 **	0	0	7 **
		<1.0>	<1.0>		<1.4>			<1.0>
Granuloma of BALT	0	0	0	0	4	0	0	0
					<1.0>			
Fibrosis of alveolar wall	0	0	0	0	10 **	0	0	0
					<1.0>			
Thickening of pleura	0	0	0	0	1	0	0	0
					<1.0>			
Lymph nodes								
Granuloma of MLN	0	4	8 **	0	4	0	0	2
		<1.0>	<1.0>		<1.0>			<1.0>

MMAD. The inhalation exposures of rats to the well-dispersed aerosols of ITO and IO resulted in depositions of ITO and IO particles in the alveolar region, which were detected in all exposed rats, except for those exposed to 0.1 mg/m³ for 2 wk. In addition, ITO and IO particles were deposited in the BALT, MLN and NALT of the exposed rats, but the extent of deposition was less in the lymph tissues and nodes than in the alveolar region. Light-microscopic examination of particle deposition in the lung and lymph nodes revealed that the particles were deposited separately as single particles.

It is interesting to note that the blood contents of indium in the male and female rats exposed to ITO at 1 mg/m³ for 13 wk were increased by 4.5- and 4.2-fold relative to the corresponding IO-exposed males and females, respectively, and that the blood contents of indium in the male and female rats exposed to 0.1 mg/m³ ITO were 0.77 and 1.13 µg/l, respectively, whereas the blood indium levels in the 0.1 mg/m³ IO-exposed rats of both sexes were below the detection limit of 0.5 µg/l. This finding can be interpreted as indicating that ITO particles are dissolved to greater

extent in the deep lung than IO, resulting in higher blood contents of indium in the ITO-exposed rats. Kabe *et al.*²²⁾ demonstrated that indium phosphide powder is clearly soluble in synthetic gastric fluid indicative of acidic pH, while the powder is insoluble in saline or synthetic lung fluid (Gamble solution). Dittmar *et al.*²³⁾ reported that when indium phosphide particles are exposed to Gamble solution, a complex dynamic interaction with the particle surface results in high levels of dissolved indium. Brain *et al.*²⁴⁾ suggested that insoluble metal particles contained in phagolysosomes of an alveolar macrophage are dissolved, because of the acidic environment (pH=4.8) in the phagolysosomes. The enhanced solubility of ITO particles in alveolar macrophages of the ITO-exposed rats warrants a further study.

The elemental or ionic form of indium leached from ITO particles is considered to play an important role in the induction of indium toxicity. Suzuki and Matsushita²⁵⁾ showed that interaction of various metallic ions with surface pressure of phospholipid monolayer mimicking a biomembrane is positively correlated with acute lethal

doses of metal chlorides in rats and rabbits, and that indium ions interact most strongly with the simulated biomembrane causing possible impairment of cellular integrity. Blazka *et al.*¹¹⁾ demonstrated that a single intratracheal administration of indium chloride dissolved in saline (pH 4.1) induces persistent inflammatory responses and development of fibrosis in rats. Lison *et al.*⁸⁾ reported that a strong cytotoxic response to ITO particles is induced *in vitro* in macrophages (NR8383 cell line) but not in rat lung epithelial cells. Taken together, it is likely that indium leached from ITO particles in the alveolar macrophages might be involved in the cellular disintegrity of alveolar macrophages, since degenerative alveolar macrophages with swollen cytoplasm engulfing ITO and IO particles were observed microscopically in the present 2- and 13-week studies.

Subacute pulmonary toxicity induced by the 2-week exposure to ITO was characterized by alveolar proteinosis, macrophage infiltration, inflammatory cell infiltration and alveolar epithelial hyperplasia. The former two pulmonary lesions occurred at exposures of 1 mg/m³ and above, while the latter two appeared primarily at exposures of 10 and 100 mg/m³. The 13-week inhalation exposure to ITO was found to induce essentially the same pulmonary lesions as those observed in the 2-week exposure, but at lower exposure concentrations. Furthermore, the histopathological examination at the end of the 26-week post-exposure period revealed development of fibrosis of alveolar wall, worsening of alveolar epithelial hyperplasia and persistence of the pulmonary lesions observed at the end of the 13-week exposure to ITO. No recovery from the subchronic effects of indium was indicated. Therefore, the present findings indicate that the pulmonary toxicity of inhaled ITO particles is more severe than that of IO particles and that alveolar macrophages play a critically important role in the induction of indium toxicity as evidenced by alveolar proteinosis, alveolar macrophage infiltration and swollen alveolar macrophages engulfing the particles, all of which occur at the lowest exposure concentration. Lison *et al.*⁸⁾ compared *in vivo* and *in vitro* pulmonary toxicity of ITO particles with those of its constituents, tin-oxide, IO and their unsintered mixture. They attributed the reactivity/toxicity of sintered ITO particles to carbon centered radical formation and Fenton-like activity, appearing with a high electron density of the sintering process through which TO molecules were introduced within crystal structure of IO²⁶⁾. However, it can be inferred from the present 2-week and 13-week studies that these pulmonary lesions are not causally linked to the dust overload induced by excessive inhalation exposure to ITO or IO aerosol, since the whole-lung contents of indium in the ITO- or IO-exposed rats were far below the levels of dust burden causing overloading, which are reported to be greater than 1–2 mg of persistently retained dust in the lungs of F344 rats²⁷⁾.

The most remarkable pulmonary lesion found in the present studies was alveolar proteinosis accompanied by alveolar macrophage infiltration. These two lesions were the most sensitive, appearing at the lowest exposure concentration. The alveolar proteinosis observed in the lung of rats exposed to ITO and IO aerosols were characterized by filling of the alveolar space with a granular, pale, eosinophilic material which is positively stained with a PAS reagent. These histological characteristics resemble those of alveolar proteinosis reported in human cases^{28, 29)}. The present result of alveolar proteinosis is consistent with reported findings that a pulmonary administration of ITO to rats and hamsters induces alveolar exudates of proteinaceous materials^{8–10)}. NTP's study¹²⁾ showed that inhalation exposure of rats to indium phosphide aerosol for 14 wk induced accumulation of proteinaceous material within the alveoli, which was diagnosed as alveolar proteinosis. The alveolar proteinosis induced by the inhalation exposures of rats to ITO and IO was similar to that seen in experimental silicosis³⁰⁾. Electron-microscopic observation³¹⁾ of the lung of rats exposed to pyro-aluminium and quartz showed that pulmonary lesion identical to human alveolar proteinosis is featured by accumulation of PAS-positive alveolar material composed primarily of pulmonary surfactant derived from Type II pneumocytes and large foamy alveolar macrophages with impaired mobility. It is notable that the present finding that the 13-week exposure of rats to 0.1 mg/m³ ITO induced moderate alveolar proteinosis with a lung content of indium at 24 µg/g lung tissue is comparable with the result of Cummings *et al.*³⁾, who reported that one of two ITO-exposed workers diagnosed as alveolar proteinosis had 29.3 µg indium per gram of lung tissue. In contrast, occurrence of alveolar proteinosis in workers exposed to ITO has not been definitely demonstrated in any epidemiological studies conducted in Japan^{2, 4–7)}. In particular, Nogami *et al.*⁶⁾ reported in their epidemiological study of workers at a Japanese indium plant that neither interstitial nor emphysematous change was recognized in the lung of a worker suffering from bronchioloalveolar carcinoma, while his lung content of indium was 31.2 µg/g lung tissue⁶⁾. These conflicting observations about the occurrence of alveolar proteinosis in indium-exposed workers remain to be resolved, although some etiological factors have been suggested^{28–31)}. Further experimental toxicology studies will be needed to explore any causative factor of alveolar proteinosis in indium-exposed rodents, including the time- and dose-related changes and species and strain differences.

In the present studies, fibrosis of alveolar wall was found to develop only at the end of 26-week post-exposure period after cessation of the 13-week exposure of rats to ITO at 0.1 mg/m³. NTP's study¹²⁾ also showed that interstitial fibrosis was induced in rats by inhalation exposure to indium phosphide aerosol for 14 wk. The

present finding that 13 wk exposure of rats to ITO induced fibrosis of alveolar wall with the indium burden indicated by 8 $\mu\text{g/g}$ lung and 1 $\mu\text{g/l}$ blood at the end of the 26-week post-exposure period can be contrasted with the case study of Homma *et al.*³²⁾, who showed that an ITO-exposed worker was diagnosed as having pulmonary fibrosis with a serum indium level of 51 $\mu\text{g/l}$. This apparent difference in the sensitivity to pulmonary fibrosis between rats and humans remains to be resolved and warrants further studies including solubility of ITO in the lung.

ACGIH's recommendation of TLV-TWA¹³⁾ for indium and its compounds of 0.1 mg/m^3 was based on pulmonary toxicity of widespread alveolar edema resembling alveolar proteinosis, resulting from 3-month inhalation exposure of rats to IO aerosol³³⁾. JSOH recommended a BEI of 3 $\mu\text{g/l}$ as a serum level of indium, below which chronic inflammation would not occur¹⁵⁾. However, it was found in the present studies that both alveolar proteinosis and alveolar macrophage infiltration are induced in rats by 13 wk inhalation exposure to ITO at 0.1 mg/m^3 , the same concentration as the ACGIH's TLV-TWA. Moreover, alveolar wall fibrosis and alveolar epithelial hyperplasia develop in all exposed rats at the end of the 26-week post-exposure period, indicating that the persistent fibro-proliferative lung lesions develops with a latent period of 26 wk after cessation of the repeated inhalation exposure to 0.1 mg/m^3 ITO. Blood contents of indium are reported to be approximately equal to serum levels of indium^{12, 34)}, while indium levels in blood instead of serum were quantified in the present studies. All the blood levels of indium in the rats exposed to ITO aerosol at 0.1 mg/m^3 measured at the end of the 13-week exposure period and at the end of the 26-week post-exposure period were below the BEI value of 3 $\mu\text{g/l}$ set by JSOH. Therefore, the present findings provide novel information about the animal basis of ITO-induced pulmonary toxicity for reconsideration of the current OEL and BEI for inhaled indium and its compounds.

We consider that an exposure concentration of 0.1 mg/m^3 ITO for 104 wk would be too high for use in a 2-year carcinogenicity study, based on the magnitude of increased lung weights and the increased incidences and severities of pulmonary lesions in the rats exposed to ITO at 0.1 mg/m^3 for 13 wk and for the 26-week post-exposure period after cessation of the 13-week exposure to 0.1 mg/m^3 . In the 2-year study, repeated exposure of rats to 0.1 mg/m^3 ITO should be discontinued at the first 26 wk, and then these rats are allowed to continue unexposed in the exposure chamber for the remainder of the study. This exposure discontinuation is based on the 1.7-fold increase in relative lung weight compared with that of the control group, the lack of recovery from alveolar proteinosis, alveolar epithelial hyperplasia, and the development of fibrosis or thickened pleural wall observed at the end of the present study's 26-week post-exposure period, and with reference

to NTP's stop-exposure rationale in the 2-year study of indium phosphide carcinogenicity¹²⁾. The middle and lowest exposure concentrations for 104 wk were selected as 0.03 and 0.01 mg/m^3 , respectively. The lowest exposure concentration of 0.01 mg/m^3 was set at the lowest concentration that generation of ITO aerosol in the present system and its chamber monitoring of the aerosol can be performed with sufficient reproducibility and accuracy.

Conclusions

Using an aerosol generator and inhalation exposure system with reproducibility and accuracy, rats of both sexes were exposed to ITO and IO at different concentrations for 2 and 13 wk. An exposure concentration-related increase in whole-lung contents of indium tended to be suppressed in the ITO- and IO-exposed rats, and blood contents of indium in the ITO-exposed rats were higher than those in the IO-exposed rats. ITO and IO particles were deposited in the lung, and to a lesser extent in the BAL, MLN and NALT of exposed rats. Two-week exposures to ITO and IO induced alveolar proteinosis, infiltrations of alveolar macrophages and inflammatory cells and alveolar epithelial hyperplasia in addition to increased lung weight. Thirteen-week exposures to ITO and IO induced the similar pulmonary lesions, and some of these lesions were worsened. ITO affected the lung more severely than did IO. Development of fibrosis and worsening of alveolar epithelial hyperplasia were noted at the end of the 26-week post-exposure period following 13 wk exposure. These ITO-induced lesions appeared at the same exposure concentration as ACGIH's TLV and at the blood indium levels below JSOH's BEI.

Acknowledgments: The present studies were contracted with and financially supported by JX Nippon Mining & Metals, Corp. (former Nippon Mining & Metals Co., Ltd.) and other 9 companies. The authors are deeply indebted to all of these companies for allowing us to publish the present studies in a scientific journal for the sake of promotion of occupational health including effective protection of workers from excessive exposure to ITO in the work environment.

References

- 1) Jorgenson JD, George MW. Mineral Commodity Profile-Indium. Open-File Report 2004-1300. US. Geological Survey, Reston, VA. [Online]. 2005 [cited 2010 Jun 16]; Available from: URL: <http://pubs.usgs.gov/of/2004/1300/2004-1300.pdf>
- 2) Homma T, Ueno T, Sekizawa K, Tanaka A, Hirata M. Interstitial pneumonia developed in a worker dealing with particles containing indium-tin oxide. J Occup Health 2003; 45: 137-9.
- 3) Cummings KJ, Donat WE, Etensohn DB, Roggli VL, Ingram P, Kreiss K. Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir

- Crit Care Med 2010; 181: 458–64.
- 4) Chonan T, Taguchi O, Omae K. Interstitial pulmonary disorders in indium-processing workers. *Eur Respir J* 2007; 29: 317–24.
 - 5) Hamaguchi T, Omae K, Takebayashi T, et al. Exposure to hardly soluble indium compounds in ITO production and recycling plants is a new risk for interstitial lung damage. *Occup Environ Med* 2008; 65: 51–5.
 - 6) Nogami H, Shimoda T, Shoji S, Nishima S. Pulmonary disorders in indium-processing workers. *J JPN Respir Soc* 2008; 46: 60–4 (in Japanese).
 - 7) Nakano M, Omae K, Tanaka A, et al. Causal relationship between indium compound inhalation and effects on the lungs. *J Occup Health* 2009; 51: 513–21.
 - 8) Lison D, Laloy J, Corazzari I, et al. Sintered indium-tin-oxide (ITO) particles: a new pneumotoxic entity. *Toxicol Sci* 2009; 108: 472–81.
 - 9) Tanaka A, Hirata M, Omura M, et al. Pulmonary toxicity of indium-tin oxide and indium phosphide after intratracheal instillations into the lung of hamsters. *J Occup Health* 2002; 44: 99–102.
 - 10) Tanaka A, Hirata M, Homma T, Kiyohara Y. Chronic pulmonary toxicity study of indium-tin oxide and indium oxide following intratracheal instillations into the lungs of hamsters. *J Occup Health* 2010; 52: 14–22.
 - 11) Blazka ME, Dixon D, Haskins E, Rosenthal GJ. Pulmonary toxicity to intratracheally administered indium trichloride in Fischer 344 rats. *Fundam Appl Toxicol* 1994; 22: 231–9.
 - 12) National Toxicology Program (NTP). Toxicology and carcinogenesis studies of indium phosphide (CAS No. 22398-80-7) in F344/N rats and B6C3F₁ mice (Inhalation studies). NTP TR 499. Research Triangle Park (NC): U.S. Department of Health and Human Service, Public Health Service, National Institute of Health; 2001.
 - 13) American Conference of Governmental Industrial Hygienists (ACGIH). Indium and compounds. In: Documentation of the threshold limit values (TLVs) and biological exposure indices (BEIs) [CD-ROM 2007]. Cincinnati (OH): ACGIH; 2001.
 - 14) National Institute for Occupational Safety and Health (NIOSH). NIOSH pocket guide to chemical hazards—Indium. [Online]. 2005 [cited 2010 Jun 10]; Available from: URL: <http://www.cdc.gov/niosh/npg/npgd0341.html>
 - 15) Japan Society for Occupational Health (JSOH). Documentation of OEL and BEI for indium and its compounds. *San Ei Shi* 2007; 49: 196–202 (in Japanese).
 - 16) Organization for Economic Co-operation and Development (OECD). OECD principles on good laboratory practice. OECD series on principles of good laboratory practice and compliance monitoring No.1. ENV/MC/CHEM (98) 17. Paris (France): OECD; 1998.
 - 17) Organization for Economic Co-operation and Development (OECD). OECD guideline for testing of chemicals. Repeated dose inhalation toxicity: 28-day or 14-day study. Adopted 12 May, 1981. Paris (France): OECD; 1981.
 - 18) Organization for Economic Co-operation and Development (OECD). OECD guideline for testing of chemicals. Subchronic inhalation toxicity: 90-day study. Adopted 12 May, 1981. Paris (France): OECD; 1981.
 - 19) National Research Council (NRC). Guide for the care and use of laboratory animals. Washington, DC: National Academies Press; 1996.
 - 20) Shackelford C, Long G, Wolf J, Okerberg C, Herbert R. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. *Toxicol Pathol* 2002; 30: 93–6.
 - 21) Aiso S, Arito H, Nishizawa T, Nagano K, Yamamoto S, Matsushima T. Thirteen-week inhalation toxicity of *p*-dichlorobenzene in mice and rats. *J Occup Health* 2005; 47: 249–60.
 - 22) Kabe I, Omae K, Nakashima H, et al. *In vitro* solubility and *in vivo* toxicity of indium phosphide. *J Occup Health* 1996; 38: 6–12.
 - 23) Dittmar TB, Fernando Q, Leavitt JA, McIntyre Jr LC. Surface concentrations of indium, phosphorus, and oxygen in indium phosphide single crystals after exposure to Gamble solution. *Anal Chem* 1992; 64: 2929–33.
 - 24) Brain JD, Curran MA, Donaghey T, Molina RM. Biologic responses to nanomaterials depend on exposure, clearance, and material characteristics. *Nanotoxicol* 2009; 3: 174–80.
 - 25) Suzuki Y, Matsushita H. Interaction of metal ions with phospholipid monolayer and their acute toxicity. *Ind Health* 1969; 7: 143–54.
 - 26) Fan JCC, Goodenough JB. X-ray photoemission spectroscopy studies of Sn-doped indium-oxide films. *J Appl Phys* 1977; 48: 3524–31.
 - 27) Morrow PE. Possible mechanisms to explain dust overloading of the lungs. *Fundam Appl Toxicol* 1988; 10: 369–84.
 - 28) Rosen SH, Castleman B, Liebow AA, et al. Pulmonary alveolar proteinosis. *The New England J Med* 1958; 258: 1123–42.
 - 29) Davidson JM, Macleod WM. Pulmonary alveolar proteinosis. *Brit J Dis Chest* 1969; 63: 13–28.
 - 30) Gross P, deTreville RTP. Alveolar proteinosis. Its experimental production in rodents. *Arch Path* 1968; 86: 255–61.
 - 31) Corrin B, King E. Pathogenesis of experimental pulmonary alveolar proteinosis. *Thorax* 1970; 25: 230–6.
 - 32) Homma S, Miyamoto A, Sakamoto S, Kishi K, Motoi N, Yoshimura K. Pulmonary fibrosis in an individual occupationally exposed to inhaled indium-tin oxide. *Eur Respir J* 2005; 25: 200–4.
 - 33) Leach LJ, Scott JK, Armstrong RD, Steadman LT, Maynard EA. The inhalation toxicity of indium sesquioxide in the rat. The University of Rochester Atomic Energy Project, Report No.UR-590. Rochester (NY): Univ of Rochester; 1961.
 - 34) Miyaki K, Hosoda K, Hirata M, et al. Biological monitoring of indium by means of graphite furnace atomic absorption spectrophotometry in workers exposed to particles of indium compounds. *J Occup Health* 2003; 45: 228–30.